Elite in Systemic Mastocytosis

Stephane Barete

Paris, FR 
Elite in Systemic Mastocytosis
Paris, FR 
OverviewLocationsClinical Research

Overview

Stephane Barete practices in Paris, France. Ms. Barete is rated as an Elite expert by MediFind in the treatment of Systemic Mastocytosis. Her top areas of expertise are Mast Cell Activation Syndrome (MCAS), Systemic Mastocytosis, Hereditary Alpha-Tryptasemia, and Livedo Reticularis.

Her clinical research consists of co-authoring 120 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 23 articles and participated in 1 clinical trial in the study of Systemic Mastocytosis.

Gender
Female

Locations

Paris, France
Other Locations
CHU de Bordeaux
Bordeaux, France
Lille, France
Poitiers, France
CHR Orléans
Orleans, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2

120 Total Publications

Real-Life Efficacy and Safety of BRAF Inhibitors in Erdheim-Chester Disease.
Real-Life Efficacy and Safety of BRAF Inhibitors in Erdheim-Chester Disease.
Journal: American journal of hematology
Published: September 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Barete's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 46 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile